ArticleOncology letters2026
Ivonescimab combined with radiotherapy in the treatment of advanced lung adenocarcinoma with high expression of PD-L1: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimal sequencing of immunotherapy and radiotherapy in non-small cell lung cancer (NSCLC) remains unclear. The present study reports a case of advanced lung adenocarcinoma (cT4N2bM1a, stage IVa) with a programmed death-ligand 1 (PD-L1) tumor proportion score of 90% and TP53 mutation. The patient received first-line ivonescimab monotherapy (900 mg, every 3 weeks) for four cycles, achieving a partial response (47% reduction per Response Evaluation Criteria in Solid Tumors 1.1). Sequential thoracic radiotherapy (5,000 cGy/25 fractions) was then administered for consolidation. Serum tumor markers (carcinoembryonic antigen, cancer antigen 125, cytokeratin 19 fragment and neuron-specific enolase) exhibited markedly decreased levels from baseline. Grade I radiation pneumonitis occurred post-radiotherapy but resolved rapidly with low-dose glucocorticoids. At the last follow-up (8 months), the patient remained progression-free with the Eastern Cooperative Oncology Group performance status improving from 2 to 0. This case provides real-world evidence for the 'immunotherapy induction followed by radiotherapy consolidation' strategy in an individual with high PD-L1 expression. The presence of TP53 mutation may predict an enhanced synergistic response to combined immunotherapy and radiotherapy, warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.